184 related articles for article (PubMed ID: 21530275)
1. Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR) α-selective agonists.
Ban S; Kasuga J; Nakagome I; Nobusada H; Takayama F; Hirono S; Kawasaki H; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2011 May; 19(10):3183-91. PubMed ID: 21530275
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.
Kasuga J; Makishima M; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2006 Feb; 16(3):554-8. PubMed ID: 16275077
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
[TBL] [Abstract][Full Text] [Related]
4. Concise and efficient asymmetric synthesis of (S)-2-ethylphenylpropanoic acid derivatives: dual agonists for human peroxisome proliferator-activated receptor alpha and delta.
Kasuga J; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2006 Feb; 16(4):771-4. PubMed ID: 16321522
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.
Nomura M; Tanase T; Ide T; Tsunoda M; Suzuki M; Uchiki H; Murakami K; Miyachi H
J Med Chem; 2003 Aug; 46(17):3581-99. PubMed ID: 12904063
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.
Suh YG; Kim NJ; Koo BW; Lee KO; Moon SH; Shin DH; Jung JW; Paek SM; Chang DJ; Li F; Kang HJ; Le TV; Chae YN; Shin CY; Kim MK; Lim JI; Ryu JS; Park HJ
J Med Chem; 2008 Oct; 51(20):6318-33. PubMed ID: 18826205
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of azaindole-alpha-alkyloxyphenylpropionic acid analogues as PPARalpha/gamma agonists.
Cai Z; Feng J; Guo Y; Li P; Shen Z; Chu F; Guo Z
Bioorg Med Chem; 2006 Feb; 14(3):866-74. PubMed ID: 16249089
[TBL] [Abstract][Full Text] [Related]
8. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.
Kasuga J; Yamasaki D; Ogura K; Shimizu M; Sato M; Makishima M; Doi T; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2008 Feb; 18(3):1110-5. PubMed ID: 18162399
[TBL] [Abstract][Full Text] [Related]
9. Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
Raval P; Jain M; Goswami A; Basu S; Gite A; Godha A; Pingali H; Raval S; Giri S; Suthar D; Shah M; Patel P
Bioorg Med Chem Lett; 2011 May; 21(10):3103-9. PubMed ID: 21450468
[TBL] [Abstract][Full Text] [Related]
10. Effects of modifications of the linker in a series of phenylpropanoic acid derivatives: Synthesis, evaluation as PPARalpha/gamma dual agonists, and X-ray crystallographic studies.
Casimiro-Garcia A; Bigge CF; Davis JA; Padalino T; Pulaski J; Ohren JF; McConnell P; Kane CD; Royer LJ; Stevens KA; Auerbach BJ; Collard WT; McGregor C; Fakhoury SA; Schaum RP; Zhou H
Bioorg Med Chem; 2008 May; 16(9):4883-907. PubMed ID: 18394907
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists.
Oon Han H; Kim SH; Kim KH; Hur GC; Joo Yim H; Chung HK; Ho Woo S; Dong Koo K; Lee CS; Sung Koh J; Kim GT
Bioorg Med Chem Lett; 2007 Feb; 17(4):937-41. PubMed ID: 17157019
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: discovery of reversed stereochemistry-activity relationship.
Ohashi M; Oyama T; Nakagome I; Satoh M; Nishio Y; Nobusada H; Hirono S; Morikawa K; Hashimoto Y; Miyachi H
J Med Chem; 2011 Jan; 54(1):331-41. PubMed ID: 21128600
[TBL] [Abstract][Full Text] [Related]
13. Design and biological evaluation of novel, balanced dual PPARalpha/gamma agonists.
Grether U; Bénardeau A; Benz J; Binggeli A; Blum D; Hilpert H; Kuhn B; Märki HP; Meyer M; Mohr P; Püntener K; Raab S; Ruf A; Schlatter D
ChemMedChem; 2009 Jun; 4(6):951-6. PubMed ID: 19326383
[TBL] [Abstract][Full Text] [Related]
14. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
15. Design of potent PPARalpha agonists.
Sauerberg P; Mogensen JP; Jeppesen L; Bury PS; Fleckner J; Olsen GS; Jeppesen CB; Wulff EM; Pihera P; Havranek M; Polivka Z; Pettersson I
Bioorg Med Chem Lett; 2007 Jun; 17(11):3198-202. PubMed ID: 17379517
[TBL] [Abstract][Full Text] [Related]
16. Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist.
Ban S; Oyama T; Kasuga J; Ohgane K; Nishio Y; Morikawa K; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2012 Jun; 20(11):3460-4. PubMed ID: 22551628
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and in vitro evaluation of a series of α-substituted phenylpropanoic acid PPARγ agonists to further investigate the stereochemistry-activity relationship.
Ohashi M; Nakagome I; Kasuga J; Nobusada H; Matsuno K; Makishima M; Hirono S; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2012 Nov; 20(21):6375-83. PubMed ID: 23022278
[TBL] [Abstract][Full Text] [Related]
18. [Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands].
Miyachi H
Yakugaku Zasshi; 2004 Nov; 124(11):803-13. PubMed ID: 15516807
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.
Yamazaki Y; Abe K; Toma T; Nishikawa M; Ozawa H; Okuda A; Araki T; Oda S; Inoue K; Shibuya K; Staels B; Fruchart JC
Bioorg Med Chem Lett; 2007 Aug; 17(16):4689-93. PubMed ID: 17553678
[TBL] [Abstract][Full Text] [Related]
20. Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part.
Kasuga J; Oyama T; Hirakawa Y; Makishima M; Morikawa K; Hashimoto Y; Miyachi H
Bioorg Med Chem Lett; 2008 Aug; 18(16):4525-8. PubMed ID: 18662876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
